Ventricular arrhythmias(VA)include premature ventricular contractions(PVC),ventricular tachycardia(VT),ventricular flutter or defibrillation(VFL/VF).Although commonly related to structural heart disease,a significant percentage of VA are idiopathic(occurring in patients with otherwise normal hearts).Classic antiarrhythmic drugs(AADs)for VA have limited effectiveness,and pose the risk of life-threatening VT/VF.Very few AADs have been successful in the last few decades,due to safety concerns or limited benefits in comparison to existing therapy.Amiodarone has emerged as the leading antiarrhythmic therapy for termination and prevention of VA in different clinical settings because of its proven efficacy and safety.For VT/VF,implantable cardioverter defibrillator(ICD)appear to be the unique,yet unsatisfactory,solution.Indications for ICD have evolved considerably from initial implantation exclusively in patients who had survived one or more cardiac arrests and failed pharmacological therapy.Multipie clinical trials have established that ICD use results in improved survival compared with antiarrhythmic agents for secondary prevention of sudden cardiac death(SCD).Large prospective,randomized,multicenter studies have also demonstrated that ICD therapy is effective for primary prevention of sudden death and improves total survival in selected patient populations who have not previously had a cardiac arrest or sustained VT.Catheter ablation is now an important option to control recurrent VT.The field has evolved rapidly and is a work in progress.Ablation is often a sole therapy of VT in patients without structural heart disease and is commonly combined with an ICD and/or antiarrhythmic therapy for scar-related VT associated with structural heart disense.